KR960021020A - 에스트로겐 작용물질 - Google Patents

에스트로겐 작용물질 Download PDF

Info

Publication number
KR960021020A
KR960021020A KR1019950049171A KR19950049171A KR960021020A KR 960021020 A KR960021020 A KR 960021020A KR 1019950049171 A KR1019950049171 A KR 1019950049171A KR 19950049171 A KR19950049171 A KR 19950049171A KR 960021020 A KR960021020 A KR 960021020A
Authority
KR
South Korea
Prior art keywords
estrogen agonists
benzothiophene
obesity
treatment
general formula
Prior art date
Application number
KR1019950049171A
Other languages
English (en)
Other versions
KR100190724B1 (ko
Inventor
디. 톰슨 데이비드
Original Assignee
알렌 제이. 스피겔
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알렌 제이. 스피겔, 화이자 인코포레이티드 filed Critical 알렌 제이. 스피겔
Publication of KR960021020A publication Critical patent/KR960021020A/ko
Application granted granted Critical
Publication of KR100190724B1 publication Critical patent/KR100190724B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

하기 일반식(1)을 갖는 벤조티오펜 및 그의 관련 화합물은 수컷 동물의 전립선 질환, 비만증 및 뼈 손실의 치료에 유용한 에스트로겐 작용물질이다:
상기 식에서, A, B, C, D, E, G, Z, Z1, X, Y 및 R 은 제1항에서 정의한 바와 같다.

Description

에스트로겐 작용물질
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (1)

  1. 내용없음
KR1019950049171A 1994-12-14 1995-12-13 에스트로겐 작용물질 KR100190724B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/356,011 US5589482A (en) 1994-12-14 1994-12-14 Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
US08/356,011 1994-12-14
US8/356011 1994-12-14

Publications (2)

Publication Number Publication Date
KR960021020A true KR960021020A (ko) 1996-07-18
KR100190724B1 KR100190724B1 (ko) 1999-06-01

Family

ID=23399729

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950049171A KR100190724B1 (ko) 1994-12-14 1995-12-13 에스트로겐 작용물질

Country Status (12)

Country Link
US (1) US5589482A (ko)
EP (1) EP0716855A2 (ko)
JP (1) JPH08231540A (ko)
KR (1) KR100190724B1 (ko)
CN (1) CN1130063A (ko)
AU (1) AU696573B2 (ko)
CA (1) CA2165012C (ko)
IL (1) IL116283A (ko)
MX (1) MX9505249A (ko)
MY (1) MY112949A (ko)
NZ (1) NZ280667A (ko)
ZA (1) ZA9510592B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100488385B1 (ko) * 2000-05-08 2005-05-11 화이자 프로덕츠 인크. 선택적인 에스트로겐 수용체 조절제의 효소적 분할 방법

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0801066A1 (en) * 1996-03-12 1997-10-15 Eli Lilly And Company Heterocyclic substituted benzothiophenes and pharmaceutical compositions
JPH10204082A (ja) * 1996-10-25 1998-08-04 Eli Lilly & Co 選択的エストロゲンレセプターモジュレーターとしての活性を有する置換されたベンゾ［ｂ］チオフェン化合物
JP2001522373A (ja) * 1997-04-30 2001-11-13 イーライ・リリー・アンド・カンパニー 抗血栓剤
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
AU9493698A (en) * 1997-09-23 1999-04-12 Eli Lilly And Company Benzothiophenes
CN1279682A (zh) 1997-10-20 2001-01-10 霍夫曼-拉罗奇有限公司 双环激酶抑制剂
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
EP1263759B1 (en) 1999-12-24 2010-09-08 Aventis Pharma Limited Azaindoles
AU2001259707A1 (en) 2000-06-14 2001-12-24 Warner Lambert Company 6,5-fused bicyclic heterocycles
EP1210951B1 (en) * 2000-11-30 2005-02-02 Pfizer Products Inc. Composition containing estrogen agonists/antagonists and testosterone for treating a decline in the level of the hormone testosterone
AU781168B2 (en) * 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
BR0313078A (pt) 2002-08-06 2005-07-12 Astrazeneca Ab Composto ou um sal deste farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou de um sal deste farmaceuticamente aceitável
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
PE20060430A1 (es) 2004-06-09 2006-05-25 Glaxo Group Ltd Derivados de pirrolopiridina como moduladores de los receptores cannabinoides
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008506702A (ja) 2004-07-14 2008-03-06 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するための方法
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7645881B2 (en) 2004-07-22 2010-01-12 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2010036497A2 (en) * 2008-09-29 2010-04-01 Eli Lilly And Company Selective estrogen receptor modulator
EP2503188B1 (de) * 2011-03-25 2015-01-21 NAF Neunkirchener Achsenfabrik AG Schaltzylinder für eine Antriebseinrichtung, insbesondere für eine selbstfahrende Arbeitsmaschine, Antriebseinrichtung, Arbeitsmaschine sowie Verfahren zum Betreiben einer Arbeitsmaschine
TR201806882T4 (tr) 2013-02-19 2018-06-21 Novartis Ag Selektif östrojen reseptörü yıkıcıları olarak benzotiofen türevleri ve bunların bileşimleri.
LT3307734T (lt) 2015-06-09 2020-05-11 Abbvie Inc. Branduolinio receptoriaus moduliatoriai (ror), skirti uždegiminių ir autoimuninių ligų gydymui
KR102542698B1 (ko) * 2022-04-05 2023-06-14 주식회사 베노바이오 신규한 벤조사이오펜 유도체 및 bet 억제제로서의 용도

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
IL65378A (en) * 1981-04-03 1986-02-28 Lilly Co Eli Process for preparing 3-(4-aminoethoxybenzoyl)benzo-(b)thiophenes
EP0062503A1 (en) * 1981-04-03 1982-10-13 Eli Lilly And Company Benzothiophene compounds and process for preparing them
US4358593A (en) * 1981-04-03 1982-11-09 Eli Lilly And Company Process for preparing 3-(4-aminoethoxybenzoyl)benzo[b]thiophenes
GB8311678D0 (en) * 1983-04-28 1983-06-02 Ici Plc Phenol derivatives
US4859585A (en) * 1986-04-17 1989-08-22 Trustees Of Tufts College In-vitro methods for identifying compositions which are agonists and antagonists of estrogens
US4970237A (en) * 1987-03-20 1990-11-13 Yale University Use of clomiphene to increase bone mass in premenopausal women
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
DE4117512A1 (de) * 1991-05-25 1992-11-26 Schering Ag 2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
US5147880A (en) * 1991-07-22 1992-09-15 Eli Lilly And Company Benzo[a]fluorene compounds
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5196435A (en) * 1991-11-21 1993-03-23 Eli Lilly And Company Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US8135386B2 (en) * 2008-07-09 2012-03-13 Telefoanktebolaget L M Ericsson (Publ) Method and apparatus for instance identifier based on a unique device identifier

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100488385B1 (ko) * 2000-05-08 2005-05-11 화이자 프로덕츠 인크. 선택적인 에스트로겐 수용체 조절제의 효소적 분할 방법

Also Published As

Publication number Publication date
CA2165012C (en) 1999-03-16
ZA9510592B (en) 1997-06-13
CA2165012A1 (en) 1996-06-15
EP0716855A3 (ko) 1996-07-10
IL116283A0 (en) 1996-03-31
MX9505249A (es) 1997-01-31
EP0716855A2 (en) 1996-06-19
US5589482A (en) 1996-12-31
JPH08231540A (ja) 1996-09-10
CN1130063A (zh) 1996-09-04
KR100190724B1 (ko) 1999-06-01
MY112949A (en) 2001-10-31
AU696573B2 (en) 1998-09-10
NZ280667A (en) 2000-08-25
IL116283A (en) 2002-02-10
AU4041295A (en) 1996-06-20

Similar Documents

Publication Publication Date Title
KR960021020A (ko) 에스트로겐 작용물질
JP2000133215A5 (ko)
JP2000052899A5 (ko)
JP2000512309A5 (ko)
JP2000507433A5 (ko)
JP2000509587A5 (ko)
JP2001527543A5 (ko)
JP2000508866A5 (ko)
JP2000510793A5 (ko)
JP2000508022A5 (ko)
JP2000512310A5 (ko)
JP2000511460A5 (ko)
JP2000511691A5 (ko)
JP2000511690A5 (ko)
JP2000509804A5 (ko)
JP2000509853A5 (ko)
JP2000511743A5 (ko)
JP2000511609A5 (ko)
JP2000513077A5 (ko)
JP2000509755A5 (ko)
JP2000512787A5 (ko)
JP2000508836A5 (ko)
JP2000511285A5 (ko)
JP2000509818A5 (ko)
FR2717697B1 (fr) Instrument d'implantation.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20011221

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee